Compare Gilead Sciences, Inc. (GILD) vs ThredUp Inc (TDUP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs ThredUp Inc — how do they compare? Gilead Sciences, Inc. trades at $134.39 (market cap $163.51B), while ThredUp Inc trades at $6.74 (market cap $858.12M). The key difference: Gilead Sciences, Inc. is far larger — about 190.5× ThredUp Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while ThredUp Inc pays none. Which is the better fit depends on your goals.
| GILD | TDUP | |
|---|---|---|
Market Cap | $163.51B | $858.12M |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $12.08 |
52-Week Low | $108.22 | $3.11 |
Enterprise Value | $178.05B | $860.86M |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
ThredUp (TDUP) trades at $6.75, up 6.47% today, with a bullish technical signal from moving averages. The company shows improving fundamentals with Q1 2026 revenue growth of 15% year-over-year to $81.7M and a strong gross margin of 79.4%. Recent developments include the launch of a peer-to-peer marketplace and AI-powered shopping tools. Analyst sentiment remains positive with 57% buy ratings and a $6.90 consensus price target, though the company continues to report net losses.
TDUP presents a turnaround story with improving revenue trends and cost management, but profitability remains elusive. The stock offers potential upside to analyst targets if execution continues, though risks include persistent losses, competitive pressures, and the need to achieve sustainable positive EBITDA. Current valuation at 2.58x sales appears reasonable for the growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About ThredUp Inc
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app, and RaaS partners.
Read more on TDUP →
